First Look: See Why GeoVax Labs (Nasdaq: GOVX) is Topping Our Early Morning Watchlist

*Sponsored Just Announced! GeoVax Labs (Nasdaq: GOVX) Tops Our Early Morning Watchlist—Take Look While It’s Still Early… This Profile Comes Backed By Several Potential Catalysts Including: With a market cap of approximately $15M as of 3/11/2025, GeoVax Labs (Nasdaq: GOVX) appears to be flying under Wall Street’s radar—for now. GeoVax Labs (Nasdaq: GOVX) has around 10M shares available, meaning even a small shift in demand could create the potential for significant swings. Analysts highlight GeoVax Labs (Nasdaq: GOVX), with one target suggesting a 1,039% upside potential. Here’s why GeoVax Labs (Nasdaq: GOVX) has earned a top spot on this morning’s watchlist March 12, 2025 Dear Reader, Last week, the therapeutics profile we brought you made an approximate 74% move within an hour of the morning bell.  Now, we’re shifting our focus to another company in a similar sector—one that could be on the verge of something big. Biotech and pharma can move fast. One major development can turn a little-known company into a headline name practically overnight. This time, our attention is on GeoVax Labs (Nasdaq: GOVX)—and it’s locked in at the top of our watchlist this morning. ( Wednesday,  (3/12/2025). With a mission to address critical health concerns, GeoVax Labs (Nasdaq: GOVX) is developing solutions for some of the most pressing medical challenges through cutting-edge science and strategic vision. Analyst’s Target Suggests 1,039% Upside Potential For  This Little-Known Biotech… Analyst coverage clearly highlights GeoVax Labs (Nasdaq: GOVX)’s considerable upside potential: According to Benzinga, D. Boral Capital has assigned an $18 target to (GOVX), which suggests over 1,039% upside potential from today’s $1.58 range. Additionally, Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, maintains a Bullish rating with a $12 target, underscoring GeoVax Labs (Nasdaq: GOVX)’s clinical momentum.  LeBoyer notes that Gedeptin’s progress into Phase 2 trials is in line with expectations and highlights CM-04S1 as aiming to provide enhanced protection compared to existing options, with key clinical data anticipated in the first half of 2025. Noble Capital Markets bases its $12 target on projected fiscal year 2026 earnings per share (EPS) of $1.45, discounted at 30% annually to reflect risks associated with the industry and market.  The firm also assigns GeoVax Labs (Nasdaq: GOVX) an 'Above Average' fundamental rating, pointing to the company’s experienced management team, robust corporate governance, and strong competitive positioning. As of yesterday, 3/11/2025, GeoVax Labs (Nasdaq: GOVX) has a market cap of approximately $15M and a public float below 10M shares.  Companies with such small market capitalization and limited float often have significant growth potential, particularly if attention begins to increase. Continue reading to discover why GeoVax Labs (Nasdaq: GOVX) is at the top of our early morning watchlist. GeoVax Labs (Nasdaq: GOVX) Advances Next-Gen Therapies With \Promising Clinical Pipeline GeoVax Labs (Nasdaq: GOVX) is engaged in developing next-generation treatments and therapies.  Its leading clinical candidate, GEO-CM04S1, has demonstrated enhanced immune responses in individuals with specific health conditions, such as Chronic Lymphocytic Leukemia (CLL).  This advancement aims to provide stronger immunity where it is needed most. Another notable project is GEO-MVA, designed to address multiple strains of a global health concern.  Given the increasing demand for innovative solutions in public health, this approach provides an avenue for broader protection.  GeoVax Labs (Nasdaq: GOVX)’s  research in oncology is also progressing, with Gedeptin currently in Phase 2 clinical trials.  This therapy explores new methods of targeting cancer cells and improving patient outcomes. GeoVax Labs (Nasdaq: GOVX) has also announced that its Phase 2 trial for Gedeptin, its gene therapy for recurrent squamous cell carcinoma of the head and neck (SCCHN), is expected to begin in the first half of 2025.  This therapy employs Gene-Directed Enzyme Therapy (GDEPT) technology, which enhances the effectiveness of treatment while minimizing its impact on surrounding healthy cells.  The trial will explore Gedeptin’s use in combination with immune-based therapies, supporting a multi-faceted approach to treatment. Beyond its clinical pipeline, GeoVax Labs (Nasdaq: GOVX) is also working to address broader national and global health concerns.  With a focus on strengthening preparedness efforts, the company is advancing technologies that align with the increasing demand for biodefense solutions. GeoVax Labs (Nasdaq: GOVX) Aligns With Market Trends as Biodefense Sector In the U.S. Alone Poised to Break $10B—And Over $37B Globally… The global biodefense market is on track to reach $19.22B in 2025 and surpass $37.16B by 2034, with the U.S. projected to account for $10.87B.  In 2023, North America contributed 41% of global revenue, a share expected to grow as governments expand investments in national security and public health. GeoVax Labs (Nasdaq: GOVX) is advancing its Modified Vaccinia Ankara (MVA) platform to support these efforts, aligning with key recommendations from the Bolstering U.S. Biodefense report.  The company is addressing critical gaps in medical preparedness and reinforcing national health initiatives by: Strengthening Supply Chains: Transitioning to domestic production to reduce reliance on foreign manufacturers. Enhancing Readiness: Developing adaptable solutions for emerging health threats. Supporting Public Health: Aligning research with global strategies to expand medical capabilities. Scaling Solutions: Refining platforms for rapid response and large-scale production to improve accessibility and efficiency. Expanding Focus & Recent Developments GeoVax Labs (Nasdaq: GOVX) is advancing medical solutions across key areas: Immune-Compromised Populations: GEO-CM04S1 is being evaluated for its potential to enhance immune responses in targeted groups. Public Health & Safety: GEO-MVA is positioned for broad-scale protection as global health concerns persist. Oncology Research: GeoVax continues exploring immune-based treatments, contributing to advancements in cancer care. Recent Developments & Strategic Moves Health Preparedness: GeoVax remains focused on addressing public health challenges through innovation. MVA-Based Research: Ongoing efforts aim to enhance the effectiveness of its Modified Vaccinia Ankara (MVA) platform. Emerging Trends: The company continuously aligns its work with evolving medical needs. Accessibility Commitment: GeoVax prioritizes making its advancements widely available, especially in underserved areas. Clinical Progress: CM-04S1 is moving forward in a BARDA-sponsored Phase 2b study set to begin in the second half of 2025. 7 Reasons We’re Keeping an Eye on GeoVax Labs (Nasdaq: GOVX) This Morning… 1. Under the Radar: With a market cap of around $15M as of 3/11/2025, GeoVax Labs (Nasdaq: GOVX) appears to be flying under Wall Street’s radar—until now. 2. Limited Float: GeoVax Labs (Nasdaq: GOVX) has approximately 10M shares in the float, meaning even a slight shift in demand could create the potential for significant swings. 3. Advancing Pipeline: GeoVax Labs (Nasdaq: GOVX) is pushing forward with Gedeptin in Phase 2 trials and GEO-CM04S1 in active development. 4 Government Initiatives: The Bolstering U.S. Biodefense Report emphasizes the need for enhanced medical readiness, aligning with GeoVax Labs (Nasdaq: GOVX)’s ongoing efforts. 5. Supply Chain Security: GeoVax Labs (Nasdaq: GOVX) aims to strengthen domestic capabilities and reduce reliance on foreign production. 6. Potential For $37B+ Market Growth: With the biodefense sector projected to surpass $37.16B by 2034, GeoVax Labs (Nasdaq: GOVX) aligns itself with a rapidly expanding space. 7. Analyst Coverage: Analysts clearly highlight GeoVax Labs (Nasdaq: GOVX)’s potential. With one analyst’s target suggesting 1,039% upside potential from today’s range.  Consider Adding GeoVax Labs (Nasdaq: GOVX) To Your  Radar This Morning… Now I have to tell you—GeoVax Labs (Nasdaq: GOVX) isn’t on everyone’s radar… yet.  But those who are paying attention might be ahead of the curve. While most people focus on names that have already grabbed headlines, this one is still flying under the radar—and if history tells us anything, early attention is where some of the most interesting setups begin. Here’s what makes this one stand out: A biopharma developing next-generation treatments, with a pipeline advancing into Phase 2. A sector projected to exceed $37B, fueled by growing government focus. A tiny market cap and low float, conditions that have historically led to significant moves when interest starts to build. Analyst targets pointing as high as $18, with another at $12—both suggesting the potential significant upside.  What happens next?  We have all eyes on GeoVax Labs (Nasdaq: GOVX) this morning. Consider taking a look at (GOVX) while it’s still early—and as always, do your own research.  Keep an eye out for my next update—it could be out to you within the next hour. Sincerely, Jeff Ackerman Managing Editor Stock News Trends Click to connect no-cost SMS (takes less than 20 seconds) StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and LFG Equities Corp., TD Media LLC has been hired for a period beginning on 03/11/2025 and ending on 03/12/2025 to publicly disseminate information about (GOVX:US) via digital communications. Under this agreement, TD Media LLC has been paid twenty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid forty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC, Media 1717 LLC, or their members own shares of (GOVX:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/govx/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice